Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Down – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares gapped down prior to trading on Thursday . The stock had previously closed at $93.29, but opened at $90.84. Oruka Therapeutics shares last traded at $85.7160, with a volume of 632,865 shares trading hands.

Analyst Upgrades and Downgrades

ORKA has been the subject of several research analyst reports. UBS Group lifted their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings downgraded Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Finally, Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Price Performance

The company’s 50-day simple moving average is $68.47 and its 200-day simple moving average is $48.77. The stock has a market capitalization of $5.07 billion, a price-to-earnings ratio of -43.43 and a beta of -0.36.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Research analysts expect that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In related news, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the completion of the sale, the director directly owned 38,743 shares in the company, valued at $2,716,271.73. The trade was a 24.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the transaction, the insider directly owned 32,718 shares in the company, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 185,407 shares of company stock valued at $11,636,307. 23.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ORKA. Legal & General Group Plc acquired a new position in shares of Oruka Therapeutics in the second quarter valued at about $28,000. BNP Paribas Financial Markets increased its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada raised its stake in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the 4th quarter worth about $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in Oruka Therapeutics in the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.